INO-1001

DB05549InvestigationalSmall molecule

Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction.

Mechanism: Pharmacologically active on Poly [ADP-ribose] polymerases
Curator reviewed
Primary indication: Investigated for use/treatment in brain cancer, cardiovascular disorders, and myocardial infarction.Curator reviewed
Formula / weight: C₂₄H₂₉N₃O₇S₂ · 535.63 g/mol (avg)
Code names: INO-1001

Resolves to

Compound

Structure

InChIKeyICMWGKNAXGUKQN-UHFFFAOYSA-NSMILESCS(O)(=O)=O.O=C1NC2=C(CC3=C2C=CC(=C3)S(=O)(=O)NCCCN2CCOCC2)C2=CC=CC=C12

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of INO-1001, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.